SA109300315B1 - بروتينات ارتباط مستقبل إنترلوكين-21 - Google Patents

بروتينات ارتباط مستقبل إنترلوكين-21 Download PDF

Info

Publication number
SA109300315B1
SA109300315B1 SA109300315A SA109300315A SA109300315B1 SA 109300315 B1 SA109300315 B1 SA 109300315B1 SA 109300315 A SA109300315 A SA 109300315A SA 109300315 A SA109300315 A SA 109300315A SA 109300315 B1 SA109300315 B1 SA 109300315B1
Authority
SA
Saudi Arabia
Prior art keywords
binding
ser
leu
gly
thr
Prior art date
Application number
SA109300315A
Other languages
Arabic (ar)
English (en)
Inventor
بلوم ليرد
جيل دافيندر
فوجميستر يوليا
يونج . ديبورا ايه
لو، ديفيد
فالج -أرتشير، فيا
Original Assignee
ميدلمون ليمتد
ويث
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SA109300315(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ميدلمون ليمتد, ويث filed Critical ميدلمون ليمتد
Publication of SA109300315B1 publication Critical patent/SA109300315B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SA109300315A 2008-05-23 2009-05-23 بروتينات ارتباط مستقبل إنترلوكين-21 SA109300315B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23

Publications (1)

Publication Number Publication Date
SA109300315B1 true SA109300315B1 (ar) 2012-08-28

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
SA109300315A SA109300315B1 (ar) 2008-05-23 2009-05-23 بروتينات ارتباط مستقبل إنترلوكين-21

Country Status (20)

Country Link
US (2) US8163884B2 (enExample)
EP (1) EP2297199A1 (enExample)
JP (1) JP2011523849A (enExample)
KR (1) KR20110040773A (enExample)
CN (1) CN102105491A (enExample)
AR (1) AR071885A1 (enExample)
AU (1) AU2009248809A1 (enExample)
CA (1) CA2724915A1 (enExample)
CL (1) CL2009001284A1 (enExample)
CO (1) CO6382184A2 (enExample)
IL (1) IL209328A0 (enExample)
MX (1) MX2010012811A (enExample)
MY (1) MY149448A (enExample)
NZ (1) NZ589330A (enExample)
PE (1) PE20100141A1 (enExample)
RU (1) RU2010152690A (enExample)
SA (1) SA109300315B1 (enExample)
TW (1) TW201000129A (enExample)
WO (1) WO2009143523A1 (enExample)
ZA (1) ZA201008335B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CN103328509A (zh) * 2009-12-25 2013-09-25 积水医疗株式会社 人胰岛素测定法和测定试剂
WO2011113027A2 (en) * 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) * 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6576744B1 (en) * 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
CN102406937A (zh) 1999-03-09 2012-04-11 津莫吉尼蒂克斯公司 新的细胞因子zalpha11配体
AU5142300A (en) 1999-05-18 2000-12-05 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
AU2001253127A1 (en) * 2000-04-05 2001-10-23 Zymogenetics Inc. Soluble zalpha11 cytokine receptors
AU2001263088B2 (en) 2000-05-11 2006-07-20 Genetics Institute, Llc. Mu-1, member of the cytokine receptor family
DE60233888D1 (de) * 2001-11-05 2009-11-12 Zymogenetics Inc Il-21-antagonisten
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
PT1531850E (pt) * 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
KR20050037552A (ko) * 2002-07-15 2005-04-22 와이어쓰 Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물
JP4914209B2 (ja) * 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
MXPA05010035A (es) 2003-03-21 2005-11-17 Wyeth Corp Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21.
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
BRPI0510996A (pt) * 2004-05-19 2007-12-04 Wyeth Corp métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
US20060039902A1 (en) 2004-08-05 2006-02-23 Young Deborah A Antagonizing interleukin-21 receptor activity
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
CL2009001284A1 (es) 2009-11-27
CA2724915A1 (en) 2009-11-26
MX2010012811A (es) 2011-05-19
WO2009143523A1 (en) 2009-11-26
MY149448A (en) 2013-08-30
AU2009248809A1 (en) 2009-11-26
US20120264919A1 (en) 2012-10-18
JP2011523849A (ja) 2011-08-25
US8163884B2 (en) 2012-04-24
EP2297199A1 (en) 2011-03-23
KR20110040773A (ko) 2011-04-20
TW201000129A (en) 2010-01-01
PE20100141A1 (es) 2010-02-22
ZA201008335B (en) 2014-04-30
US20090298167A1 (en) 2009-12-03
RU2010152690A (ru) 2012-06-27
CN102105491A (zh) 2011-06-22
AR071885A1 (es) 2010-07-21
NZ589330A (en) 2012-12-21
CO6382184A2 (es) 2012-02-15
IL209328A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
CN111171150B (zh) 抗人tslp抗体及其用途
US20240132603A1 (en) Ccr8 antibody and application thereof
CN106939050B (zh) 抗pd1和cd19双特异性抗体及其应用
CN110357963B (zh) 抗人st2抗体及其用途
SA109300315B1 (ar) بروتينات ارتباط مستقبل إنترلوكين-21
US20200002415A1 (en) Binding molecules specific for fcgamma riia and uses thereof
CN106967172A (zh) 抗ctla4‑抗pd‑1 双功能抗体、其药物组合物及其用途
CN102089326A (zh) 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
JP7457822B2 (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
KR20110021919A (ko) 인터루킨-21 수용체의 결합 단백질을 사용하는 치료 방법
CN116133684B (zh) 抗人nr1抗体衍生物
WO2021143914A1 (zh) 一种激活型抗ox40抗体、生产方法及应用
CN118251419A (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
CN109705217B (zh) 抗il-13抗体及其用途
CN112375146B (zh) 检测Anti-CD19 CAR表达水平的抗独特性抗体及其应用
KR20160125965A (ko) 신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체
WO2022247826A1 (zh) 靶向pd-l1和cd73的特异性结合蛋白
US20220411523A1 (en) Molecule capable of binding to human 4-1bb and its application thereof
TW202216775A (zh) 位點特異性Notch活化分子及其用途
CN115947855B (zh) 抗cd24抗体的制备及其用途
TWI795872B (zh) 抗gm2ap抗體及其應用
CN115521378B (zh) Pd-l1抗体及其用途
WO2020248156A1 (zh) Pd-l1靶向结合剂及其用途
US20240409617A1 (en) Multispecific coronavirus antibodies
WO2024094159A1 (zh) 靶向人源ror1的单域抗体